Varicose Vein Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Varicose veins are enlarged, tortuous, superficial veins that protrude visibly beneath the skin, most commonly in the legs and feet. They develop when venous valves — which normally prevent retrograde blood flow — become incompetent, allowing blood to pool and increasing hydrostatic pressure within the vein wall. The resulting distension and elongation produce the characteristic bulging, rope-like appearance that affects an estimated 23–35% of adults in Western countries, with women affected nearly twice as often as men.

The underlying pathophysiology is chronic venous insufficiency (CVI), a progressive condition driven by sustained venous hypertension. Incompetent valves in the great saphenous vein (GSV), small saphenous vein (SSV), or perforating veins allow venous reflux lasting more than 0.5 seconds on duplex ultrasound — the diagnostic threshold for haemodynamically significant disease. Over time, this causes progressive skin changes, oedema, lipodermatosclerosis, and ultimately venous ulceration in the most severe cases.

Risk factors include prolonged occupational standing or sitting, obesity (BMI >30), pregnancy, strong family history (heritability estimated at 40–60%), previous deep vein thrombosis (DVT), and advancing age. Though often perceived as a cosmetic issue, varicose veins represent a chronic disease spectrum classified using the internationally standardised CEAP system (Clinical-Etiological-Anatomical-Pathophysiological), ranging from C0 (no visible disease) through C6 (active venous ulcer).

The landscape of varicose vein treatment has been transformed over the past two decades. Open surgical ligation and stripping — once the standard of care — has been largely superseded by minimally invasive, office-based or day-case procedures. Endovenous laser ablation (EVLA), radiofrequency ablation (RFA), cyanoacrylate closure, mechanochemical ablation (MOCA), and foam sclerotherapy are now endorsed by major international guidelines from the Society for Vascular Surgery (SVS), American Venous Forum, European Venous Forum, and NICE (UK) as first-line approaches for suitable anatomy. Treatment selection is guided by duplex ultrasound mapping of reflux patterns, vein diameter, and patient preference.

Varicose vein treatments address a spectrum of venous disorders across all CEAP severity stages:

• Primary varicose veins (CEAP C2): Trunk varices >3 mm in diameter arising from GSV or SSV incompetence. The most common indication for treatment, presenting with aching, heaviness, throbbing, itching, and cosmetic concerns. Duplex-confirmed axial reflux must be identified before treating tributary varices alone.
• Telangiectasias and reticular veins (CEAP C1): Spider veins <1 mm and intradermal reticular veins 1–3 mm. Treated primarily for cosmetic reasons using fine-needle sclerotherapy or transdermal laser. Not typically associated with significant haemodynamic reflux.
• Chronic venous oedema (CEAP C3): Ankle and lower leg swelling caused by elevated venous pressure impairing lymphatic drainage. Correction of the underlying reflux reduces oedema in approximately 60% of cases.
• Skin changes — lipodermatosclerosis and pigmentation (CEAP C4): Chronic inflammation from venous hypertension causes subcutaneous fibrosis, hyperpigmentation (haemosiderin deposition), and atrophie blanche. Treatment halts progression and promotes skin recovery.
• Healed venous ulcer (CEAP C5) and active venous ulcer (CEAP C6): Venous leg ulcers affect 1–2% of the population over a lifetime. The landmark EVRA trial (NEJM, 2018) demonstrated that early endovenous ablation — within 2 weeks of ulcer presentation — reduces median healing time from 82 to 56 days compared to compression alone and increases the proportion healed at 24 weeks from 55% to 85%.
• Superficial thrombophlebitis: Inflammatory thrombosis in a varicose segment, causing a painful, tender, erythematous cord. Acute management with NSAIDs and anticoagulation is followed by elective varicose vein treatment to prevent recurrence and extension to the deep venous system.
• Variceal haemorrhage: Rupture of a large superficial varix — typically at the ankle — can cause alarming but rarely life-threatening external haemorrhage. Emergency compression is followed by elective ablation as definitive treatment.

Eligibility is determined through clinical assessment and duplex ultrasound mapping. Key criteria include:

• Symptomatic disease: Patients with CEAP C2 or above presenting with aching, heaviness, swelling, itching, restlessness, or skin changes are appropriate candidates. Asymptomatic patients with CEAP C2 veins may also be offered treatment for quality-of-life reasons after shared decision-making.
• Haemodynamically significant reflux on duplex ultrasound: Axial reflux >0.5 seconds in the GSV, SSV, or perforating veins must be confirmed. Treating tributary varices without addressing the reflux source carries a high recurrence rate.
• Trial of conservative measures: Compression hosiery, weight management, and exercise should be trialled for at least 6 weeks in uncomplicated cases before offering intervention. Compression is contraindicated where the ankle-brachial pressure index (ABPI) is <0.6 due to arterial disease.
• Complications of varicose veins: Patients with active or healed venous ulcers (C5/C6), recurrent superficial thrombophlebitis, or variceal haemorrhage are generally prioritised for early treatment regardless of symptom burden.
• Anatomy suitable for endovenous access: EVLA and RFA require a straight accessible segment of GSV or SSV >3 mm in diameter. Highly tortuous veins, veins <3 mm in calibre, or those running <1 cm from the skin surface may require technique modification or alternative approaches such as MOCA or cyanoacrylate.
• Contraindications to consider: Active DVT, known allergy to sclerosing agents (for foam sclerotherapy), pregnancy (relative contraindication — defer elective treatment until at least 3 months after delivery), immobility (inability to walk post-procedure increases DVT risk), and severe peripheral arterial disease (ABPI <0.6).

Pre-operative workup includes history and clinical examination using the CEAP classification, Venous Clinical Severity Score (VCSS), and a formal duplex ultrasound mapping study to define the extent of reflux and guide the optimal therapeutic strategy.

A range of evidence-based interventions is available, selected based on anatomy, disease extent, and patient preference:

1. Compression therapy (conservative first-line): Class II graduated compression hosiery (18–24 mmHg at the ankle) reduces venous hypertension, controls oedema, and improves symptoms in most CEAP C2–C4 patients. While not curative, it is effective when worn consistently and recommended before and after procedural interventions to reduce recurrence rates.
2. Ultrasound-guided foam sclerotherapy (UGFS): A liquid sclerosant (polidocanol or sodium tetradecyl sulphate, STS) is converted to foam using the Tessari technique (mixing sclerosant with CO₂ or air in a 1:4 ratio), then injected under ultrasound guidance into the target vein. Foam displaces blood, causes endothelial injury, thrombosis, and fibrosis. Technical success approximately 60–80% at 5 years; multiple sessions are often required. Preferred for recurrent varicosities, anatomically complex anatomy, or large-calibre veins where ablation is unsuitable.
3. Endovenous laser ablation (EVLA/EVLT): A fibre-optic laser probe is inserted percutaneously into the GSV or SSV under ultrasound guidance, positioned 2 cm distal to the sapheno-femoral junction, and withdrawn while delivering thermal energy (810–1940 nm wavelengths). Tumescent local anaesthesia is infiltrated perivenously before ablation. Achieves 95–98% technical closure at 1 year. Modern 1470 nm and 1940 nm wavelengths targeting water in the vein wall cause less post-procedural pain and bruising than earlier 810–980 nm devices.
4. Radiofrequency ablation (RFA, VNUS ClosureFAST): A radiofrequency catheter heats the vein wall to 120°C in controlled 20-second treatment cycles, with stepwise segmental withdrawal. Equivalent efficacy to EVLA (95–97% closure at 1 year). Multiple RCTs and meta-analyses confirm slightly less post-procedure pain and bruising compared to laser, with equivalent durability at 5 years. The RECOVERY trial (2010) established its superiority over surgery for patient-centred outcomes.
5. Cyanoacrylate closure (VenaSeal, Medtronic): Medical-grade cyanoacrylate adhesive is injected into the GSV under ultrasound guidance, occluding it by mechanical and inflammatory mechanisms. No tumescent anaesthesia is required, and post-procedural compression stockings are optional. Published closure rates of 94–99% at 1–3 years (e-CLOSURE registry, 2018). Particularly useful in anticoagulated patients, those with needle intolerance, or superficially running veins where thermal injury risk is high.
6. Mechanochemical ablation (MOCA, ClariVein): A rotating wire tip mechanically injures the endothelium while simultaneously infusing liquid sclerosant, combining mechanisms of injury without thermal energy. No tumescent anaesthesia required. Closure rates of 85–92% at 2 years. Suited to tortuous veins or those lying <1 cm from the skin surface.
7. Ambulatory phlebectomy (Muller phlebectomy): Under local anaesthesia, tributary varices are removed through micro-incisions (2–3 mm) using a phlebectomy hook. Often performed concurrently with trunk ablation or as a staged procedure 6 weeks later. Immediate ambulation is encouraged. Produces excellent cosmetic results with minimal scarring.
8. High ligation and stripping (traditional surgery): Division of the sapheno-femoral junction and surgical stripping of the GSV under general or spinal anaesthesia. Now reserved for patients unsuitable for endovenous techniques (very large-calibre veins, complex anatomy, failed endovenous procedures). Associated with higher post-operative pain and recurrence rates (25–40% at 10 years) compared to thermal ablation.

Effective treatment of varicose veins delivers clinical, functional, and quality-of-life benefits that extend well beyond cosmetic improvement:

• Symptom relief: Approximately 80–90% of patients experience significant or complete resolution of aching, heaviness, swelling, itching, and leg fatigue following successful ablation. Symptom relief is typically evident within 2–4 weeks of treatment and sustained at long-term follow-up.
• Prevention of disease progression: Untreated CVI advances in up to 30% of patients over 5–10 years, from varicose veins to skin changes to venous ulceration. Early intervention interrupts this progression and significantly reduces the lifetime risk of venous ulceration — a chronic, debilitating, and costly complication.
• Venous ulcer healing acceleration: The EVRA trial (NEJM, 2018) demonstrated that early endovenous ablation alongside compression reduces median ulcer healing time by 26 days and increases the proportion healed at 24 weeks from 55% (compression alone) to 85%. This evidence has transformed the management of active venous leg ulcers.
• Quality-of-life improvement: Validated instruments including the Aberdeen Varicose Vein Questionnaire (AVVQ) and SF-36 consistently demonstrate significant improvements in disease-specific and general quality of life following treatment, with benefits persisting at 5-year follow-up in randomised trials.
• Minimally invasive, outpatient options: Modern endovenous techniques are performed under local anaesthesia in 45–90 minutes. Most patients return to desk work within 1–3 days. This eliminates the risks, discomfort, and prolonged recovery associated with general anaesthesia and inpatient surgery.
• High technical success with durable results: EVLA and RFA achieve 95–98% closure rates at 1 year, with 80–85% of treated veins remaining closed at 5 years, a durability superior to traditional surgical stripping for most patient groups.
• Reduced thrombophlebitis and DVT risk: Elimination of incompetent venous segments reduces inflammatory episodes and venous stasis in adjacent systems, lowering the risk of superficial thrombophlebitis and deep vein thrombosis over the long term.

Varicose vein treatments are generally safe with modern minimally invasive techniques, but potential complications should be discussed with all patients:

• Endovenous heat-induced thrombosis (EHIT) and DVT: Thermal ablation techniques carry a risk of thrombus propagating from the ablated superficial vein into the deep venous system (EHIT) in 1–3% of cases. Most are low-grade (class 1–2) and resolve spontaneously or with short-term anticoagulation. Clinically significant DVT requiring therapeutic anticoagulation occurs in <1% of endovenous procedures. A duplex scan at 48–72 hours post-procedure detects EHIT.
• Nerve injury: The saphenous nerve (parallel to the below-knee GSV) and the sural nerve (adjacent to the SSV) are at risk of thermal injury. Paraesthesia or numbness occurs in 2–7% of cases, typically resolving within 3–6 months. Careful probe positioning and adequate tumescent anaesthesia minimise this risk.
• Skin burns and thermal injury: Inadequate tumescent anaesthesia or veins lying <1 cm from the skin surface can result in skin burns during EVLA or RFA. Incidence <1% with modern wavelengths and careful technique. MOCA and cyanoacrylate closure eliminate thermal injury risk entirely.
• Post-sclerotherapy skin pigmentation: Haemosiderin deposition following foam sclerotherapy causes hyperpigmentation in 15–30% of patients. It generally fades over 6–12 months but can be permanent in some individuals with darker skin tones.
• Thrombophlebitis: Inflammatory reaction in treated or adjacent veins produces painful, palpable cord-like segments in 3–8% of cases. Managed with NSAIDs and compression; generally resolves within 2–4 weeks.
• Haematoma and bruising: More common after ambulatory phlebectomy and surgical stripping than endovenous ablation. Most resolve without intervention; large haematomas occasionally require aspiration.
• Allergic reactions to sclerosant: Anaphylaxis to polidocanol or STS is rare (<0.01%) but potentially severe. A test dose approach in patients with prior allergic history reduces this risk.
• Recurrence of varicose veins: New varicosities develop in 15–20% of patients within 5 years due to disease progression in untreated veins, perforator incompetence, or neovascularisation at the groin — particularly after open surgery. Consistent compression hosiery wear and lifestyle modification reduce recurrence risk.

Post-procedural follow-up is essential to confirm technical success, detect complications, and maintain long-term results:

• Immediate post-procedure activity: Patients undergoing endovenous ablation are encouraged to walk for at least 30 minutes immediately after the procedure before leaving the clinic. Walking activates the calf muscle pump, reduces DVT risk, and helps displace residual sclerosant. Compression bandages or stockings are applied before the patient stands.
• Post-procedure compression: Class II compression stockings (18–24 mmHg) are recommended for 7–14 days following EVLA, RFA, or foam sclerotherapy, worn for the majority of waking hours. Evidence supports 7 days of compression as equivalent to 14 days for most patients. Cyanoacrylate closure does not require mandatory post-procedure compression, though many operators recommend it for comfort.
• 72-hour duplex ultrasound scan: A post-procedure duplex scan at 48–72 hours is recommended by SVS and NICE guidelines to screen for EHIT at the sapheno-femoral or sapheno-popliteal junction. If EHIT class 2 or above is identified (thrombus reaching the common femoral or popliteal vein), anticoagulation is initiated.
• Activity guidance: Return to desk work within 1–3 days; manual or physically demanding work after 1–2 weeks. Swimming and gym exercise are permitted at 2 weeks. Prolonged standing and heat (baths, saunas, hot yoga) should be avoided for 2 weeks. Compression stockings must be worn during long-haul flights.
• 4–6 week review: Clinical review with repeat duplex ultrasound assesses GSV/SSV closure (confirmed by absence of compressible lumen and colour-flow signal), identifies any residual reflux, and plans adjunctive foam sclerotherapy for residual tributary varices if needed. Most patients require one follow-up sclerotherapy session for optimal cosmetic results.
• Long-term lifestyle measures: Annual clinical review is recommended for patients with severe CVI (C3–C6). Patients should be counselled that varicose veins reflect a chronic underlying condition — long-term compression hosiery, weight management, regular exercise (walking, cycling), and leg elevation remain important throughout life to minimise disease progression and recurrence.

The cost of varicose vein treatment varies considerably based on multiple factors:

• Treatment modality: Compression hosiery is the least expensive option (USD 30–100 per pair). Foam sclerotherapy costs approximately USD 200–800 per session. Endovenous ablation (EVLA or RFA) typically costs USD 1,500–4,000 per leg in the USA and USD 400–1,200 in India and medical tourism destinations. Cyanoacrylate and MOCA carry higher disposable device costs. Surgical ligation and stripping adds anaesthetic and hospital facility fees.
• Extent of disease: Bilateral treatment, long GSV or SSV disease segments, and the need for multiple sclerotherapy sessions for residual tributaries multiply overall costs. Many patients require 2–3 staged treatment visits for complete disease clearance.
• Pre-procedural duplex mapping: A formal duplex ultrasound mapping study by an accredited vascular sonographer is essential and adds USD 200–600 to the initial assessment cost. Follow-up duplex scans at 72 hours and 6 weeks contribute further.
• Facility setting: Office-based procedures under local anaesthesia are significantly less expensive than hospital-based day-case procedures or those requiring general anaesthesia, IV sedation, and full operating theatre resources.
• Insurance and public funding: In the UK (NHS), treatment of symptomatic CEAP C2 or above is publicly funded, though waiting times apply. In the USA, Medicare and most private insurers cover endovenous ablation for symptomatic patients after documented failure of conservative therapy (typically 6 weeks of compression). Spider veins and purely cosmetic treatments are usually self-funded.
• Medical tourism: India, Thailand, Hungary, and Turkey offer high-quality endovenous treatment at 40–70% of UK or US prices, with experienced vascular surgeons and internationally accredited facilities. International patients should verify surgeon credentials, facility accreditation, and post-procedure follow-up arrangements before travelling.
• Cost of non-treatment: Progression to venous ulceration carries substantial long-term costs in community nursing, dressings, and lost productivity. Treatment of a venous ulcer over 12 months typically costs EUR 800–3,000 in direct medical costs alone, making early intervention cost-effective from a health-economic perspective.

For patients who prefer to avoid or defer procedural treatment, conservative strategies can manage symptoms and slow disease progression:

• Graduated compression hosiery: Class II (18–24 mmHg) or Class III (25–35 mmHg) compression stockings are the cornerstone of conservative management. When worn consistently, they significantly reduce symptoms in the majority of patients. Compliance is challenging — particularly in hot climates, elderly patients, and those with limited hand dexterity or arthritis — and stockings must be replaced every 3–6 months to maintain therapeutic pressure.
• Leg elevation: Elevating the legs above the level of the heart for 30 minutes three to four times daily reduces venous pressure and oedema. Simple, cost-free, and recommended as an adjunct to all treatments. Most effective when combined with compression.
• Exercise and weight management: Regular low-impact exercise — walking, cycling, swimming — activates the calf muscle pump, the most powerful mechanism for venous return from the lower limbs. Weight loss in obese patients (BMI >30) reduces intra-abdominal pressure and venous hypertension. Obesity is an independent predictor of increasing CEAP score progression over time.
• Phlebotonic drug therapy: Horse chestnut seed extract (HCSE, standardised to aescin 50 mg twice daily) has demonstrated modest but significant reductions in leg oedema and symptoms in randomised trials. A Cochrane review concluded it is superior to placebo and comparable to compression in short-term symptom control. Micronised purified flavonoid fraction (MPFF/Daflon 500) is widely used in Europe and Asia with evidence supporting reduction in CVI symptoms, oedema, and venous ulcer healing time.
• Surveillance without treatment: Asymptomatic patients with incidentally discovered varicose veins who accept the small risk of progression may opt for watchful waiting with periodic reassessment. Annual clinical review and duplex ultrasound is recommended to monitor for disease progression to higher CEAP grades.
• Wound care for venous ulcers: In patients who are not candidates for intervention due to comorbidity or frailty, optimal wound care — multilayer compression bandaging, moist wound healing, debridement, and infection management — can achieve ulcer healing. However, healing rates are substantially lower and recurrence substantially higher than with concurrent venous ablation, making it a less effective long-term strategy.